Please login to the form below

Not currently logged in
Email:
Password:

ABPI pledges greater payment transparency

UK pharma trade body updates Code of Practice
ABPI London offices

A change to the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice is intended to provide greater transparency for payments to healthcare professionals and organisations.

A recent industry consultation found respondents overwhelmingly in favour of public disclosure of payments within the healthcare professional community and across commercial life sciences companies.

Almost 90 per cent of 1,055 respondents agreed that payments to individually named healthcare professionals by companies should be transparent and publicly declared.

The ABPI is considering a number of potential methods of disclosure, with 80 per cent of survey respondents in favour of a single, publically searchable, central database.

A consultation about the proposed change is expected to take place in summer 2014, and the ABPI says that the 2015 code is likely to include requirements about the method of disclosure.

“For too long the industry has suffered from a common misunderstanding around the nature of its relationship with healthcare professionals,” said ABPI chief executive Stephen Whitehead.

“The changes to the code are part of the industry's attempt to address this misunderstanding and to enhance transparency around these relationships. We hope this will allow us to foster greater trust between the medical community, industry and patients.”

Changes to the code are being made to implement the European Federation of Pharmaceutical Industries and Associations code on the disclosure of transfers of value from pharmaceutical companies to health care organisations and professionals, the ABPI said.

The changes refer to information which should be collected in 2015 for disclosure in 2016.

Article by
Tara Craig

14th November 2013

From: Marketing, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics